GLP-1 Receptor Agonist Efficacy for Insulin Resistance Treatment
The management of type 2 diabetes mellitus (T2DM) and insulin resistance requires a multifaceted approach, incorporating lifestyle modifications and pharmacological interventions. Among the various therapeutic options, glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as a pivotal treatment modality, demonstrating efficacy in blood glucose management, weight reduction, cardiovascular disease prevention, and kidney health improvement.
GLP-1 Receptor Agonist Mechanism of Action
GLP-1RAs mimic the effects of the incretin hormone glucagon-like peptide-1 (GLP-1), which plays a crucial role in glucose regulation and appetite suppression. GLP-1 stimulates insulin release from the pancreas, inhibits glucagon secretion, slows gastric emptying, and sends satiety signals to the brain, thereby regulating blood sugar levels.
GLP-1 Receptor Agonist Clinical Applications
GLP-1RAs have been widely recognized for their therapeutic benefits in managing T2DM, insulin resistance, and associated comorbidities. Studies have demonstrated the efficacy of GLP-1RAs in reducing hemoglobin A1c (HbA1c) levels, body weight, and waist circumference, as well as improving lipid profiles and cardiovascular risk factors.
GLP-1 Receptor Agonist Patient Selection
GLP-1RAs are recommended for patients with T2DM and/or obesity, including those with elevated HbA1c levels, body mass index (BMI) above 30 kg/m2, and increased cardiovascular risk. Patients with a history of pancreatitis, thyroid cancer, or glucagonoma are contraindicated for GLP-1RA therapy.
